NOTVQ
Inotiv, Inc.Key Statistics
About Inotiv, Inc.
Inotiv, Inc. (NOTVQ) is a prominent preclinical contract research organization that provides essential drug development and safety assessment services tailored for the biotech and pharmaceutical industries. The company offers a diverse array of solutions, including nonclinical imaging, pharmacology, and toxicology, which are critical in advancing the development of innovative therapeutics. With a focus on leveraging cutting-edge technologies and a highly competent workforce, Inotiv effectively delivers actionable insights that accelerate drug discovery processes. Positioned strategically within the expanding life sciences sector, Inotiv is well-equipped to meet the mounting demand for outsourced research and development services.
Fundamentals
| Revenue (TTM) | $507.36M |
| Gross Profit (TTM) | $116.41M |
| EBITDA | $8.56M |
| Operating Margin | -16.00% |
| Return on Equity | -74.10% |
| Return on Assets | -4.02% |
| Revenue/Share (TTM) | $14.73 |
| Book Value | $2.21 |
| Price-to-Book | 0.01 |
| Price-to-Sales (TTM) | 0.00 |
| EV/Revenue | 0.932 |
| EV/EBITDA | 68.66 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -5.40% |
| Shares Outstanding | $35.17M |
| Float | $32.62M |
| % Insiders | 8.56% |
| % Institutions | 13.61% |
Historical Volatility
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on NOTVQ and any ticker you trade — then tracks every position and per-strategy win rate.